Our Cell & Gene offering spans across development and manufacturing services, products, solutions, testing and automation platforms as well as tools and technologies to enable you to develop, de-risk and industrialize your therapy, from basic research to commercialization.
Oxford Biomedica Solutions
Oxford Biomedica - A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your partner of choice for viral vector development scale-up, analytics and GMP processing.
Leverage our expertise and state-of-the-art bioprocessing facilities and purpose-built laboratories to help to achieve commercialization of your viral vector-based products.
Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Cabaletta Bio, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations. Additionally, Oxford Biomedica has a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Oxford Biomedia Solutions, a US-based subsidiary, offers a plug and play platform that is capable of achieving both high titer and high product quality vector for partners. The platform has already been proven with six separate new product INDs and CTAs. High titer, high product quality, proven expertise, and speed are the foundation of the platform. This unique platform and fully integrated end-to-end capabilities, from vector design and process development through to clinical trials. For more information, visit oxb.com.
Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers through our Patheon brand. With more than 65 locations around the world, we provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics services and commercial manufacturing and packaging.
Built on a reputation for scientific and technical excellence, we provide pharma and biotech companies of all sizes instant access to a global network of facilities and experts across the Americas, Europe, Asia and Australia. We offer integrated drug development and clinical services tailored to fit your drug development journey through our Quick to CareTM program. Our Quick to ClinicTM programs for large and small molecules help you balance speed and risk during early development so you can file your IND quickly and successfully. Digital innovations such as our mysupply Platform and Pharma 4.0 enablement offer real-time data and a streamlined experience. Together with our customers, we’re rapidly turning pharmaceutical possibilities into realities.
PackGene is a world-leading AAV vector packaging CRO and CDMO. Founded in Massachusetts, USA, PackGene now has offices in Guangzhou, Shanghai, Boston, Houston and Zurich. We work with customers to support gene therapy programs from early-stage R&D, preclinical development, to IND studies. Our mission is to accelerate gene therapy product development by providing an integrated one stop solution including plasmid, viral vector, fill-finish and QC analytical services for the gene therapy industry